3 hours Ago By ABMN Staff
Victory Capital Management Inc. boosted its stake in shares of Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX – Free Report ) by 1.
6% during the fourth quarter, HoldingsChannel.com reports. The firm owned 296,080 shares of the biopharmaceutical company’s stock after acquiring an additional 4,575 shares during the period.
Victory Capital Management Inc.’s holdings in Catalyst Pharmaceuticals were worth $6,179,000 as of its most recent SEC filing. Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company.
JPMorgan Chase & Co. grew its position in Catalyst Pharmaceuticals by 9.1% during the third quarter.
JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock valued at $8,116,000 after purchasing an additional 33,888 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in Catalyst Pharmaceuticals by 13.
9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company’s stock worth $8,710,000 after acquiring an additional 50,888 shares in the last quarter. Wellington Management Group LLP bought a new stake in Catalyst Pharmaceuticals in the third quarter worth approximately $1,185,000.
Redhawk Wealth Advisors Inc. bought a new stake in Catalyst Pharmaceuticals in the fourth quarter worth approximately $1,273,000. Finally, Spire Wealth Management grew its position in Catalyst Pharmaceuticals by 1,342.
9% in the fourth quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 13,429 shares in the last quarter. 79.
22% of the stock is owned by hedge funds and other institutional investors. Analyst Upgrades and Downgrades Several analysts have commented on CPRX shares. Robert W.
Baird boosted their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd.
Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th.
StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Finally, Stephens reaffirmed an “overweight” rating and set a $33.
00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.
com, the stock presently has an average rating of “Buy” and a consensus target price of $32.50. Insider Transactions at Catalyst Pharmaceuticals In related news, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction dated Monday, March 3rd.
The stock was sold at an average price of $22.98, for a total value of $1,447,165.50.
Following the completion of the sale, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This trade represents a 25.
04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink . Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th.
The shares were sold at an average price of $22.09, for a total value of $991,929.36.
Following the transaction, the insider now directly owns 68,873 shares of the company’s stock, valued at $1,521,404.57. The trade was a 39.
47 % decrease in their position. The disclosure for this sale can be found here . Insiders own 11.
00% of the company’s stock. Catalyst Pharmaceuticals Price Performance Shares of NASDAQ CPRX opened at $21.02 on Friday.
The company has a 50 day simple moving average of $22.26 and a 200 day simple moving average of $21.52.
The firm has a market cap of $2.55 billion, a PE ratio of 17.81, a price-to-earnings-growth ratio of 3.
31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc.
has a 1 year low of $14.47 and a 1 year high of $24.64.
Catalyst Pharmaceuticals Company Profile ( Free Report ) Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. Recommended Stories Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX – Free Report ). Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
